secwatch.observer — SEC 8-K summary
======================================

Issuer:     cbdMD, Inc. (YCBD)
CIK:        0001644903
Form:       8-K
Filed at:   2026-04-01T23:59:59+00:00
Accession:  0001437749-26-010878
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shareholders approve reverse stock split, dilutive share issuances, and 2025 equity plan at cbdMD annual meeting
--------------------------------------------------------------------------------

- Reverse stock split from 1:2 to 1:10 approved, board to set ratio within one year.
- Approved issuance of >20% of outstanding shares upon conversion of Series B and Series C Preferred and under ELOC with C/M Capital.
- 2025 Equity Compensation Plan approved with 891,316 initial shares plus 2% annual evergreen (max 300,000/year).
- CEO Kennedy receives 445,000 restricted shares under the newly approved plan.
- All seven director nominees elected; Cherry Bekaert LLP ratified as auditor for FY2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1644903/000143774926010878/0001437749-26-010878-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1644903/000143774926010878/ycbd20260330_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-010878

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer